NCT04508725

Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)

Early Therapeutic Monitoring of Response to Therapy With Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: Stanford University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To assess whether changes in quantitative tumor perfusion parameters after 3 or 6 weeks of treatment, as measured by power Doppler ultrasound, can predict initial objective response, defined by current standard-of-care, to therapy at 12 weeks after start of treatment

Conditions

• Kidney Cancer
• Renal Cell Carcinoma
• Metastatic Renal Cell Carcinoma

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Doppler Ultrasound	Power Doppler measurements will be made
DEVICE	SIEMENS S3000 and Verasonics Vantage 256	Vantage 256 used for power Doppler ultrasound, manufactured by Verasonics
DRUG	Standard-of-care Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI)	Standard-of-care Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI).
DRUG	Standard-of-care non-immune checkpoint inhibitor (ICI) such as single-agent VEGFR2 TKI	Standard-of-care non-immune checkpoint inhibitor (ICI) such as single-agent VEGFR2 TKI

Timeline

• Start date: 2020-12-05
• Primary completion: 2023-11-30
• Completion: 2023-11-30
• First posted: 2020-08-11
• Last updated: 2025-07-25
• Results posted: 2025-07-25

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated device study